AZD8309 is an orally active antagonist of CXCR2 . AZD8309 has the ability to regulate the transmigration of neutrophils. AZD8309 can be used in the study of inflammatory diseases In Vivo AZD8309 (50 mg/kg; p.o.; twice daily) reduces neutrophil migration and pancreatic protease activation in experimental pancreatitis in mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male C57BL6 mice (25-30 g) with experimental pancreatitis Dosage: 50 mg/kg Administration: Oral gavage; twice daily starting 3 h prior to pancreatitis induction Result: Significantly reduced MPO in the pancreas and lungs (8 h & 24 h) and reduced intrapancreatic trypsin and elastase activity (8 h) in caerulein-pancreatitis. Reduced serum cytokine levels as well as histopathological damage. Form:Solid IC50& Target:CXCR2
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
AZD8309
CAS number：333742-48-6 molecular formula：C15H14F2N4O2S2
overview
compound introduction
Specs
| Chinese alias | - | ||
| English alias | - | ||
| CAS number | 333742-48-6 | molecular formula | C15H14F2N4O2S2 |
| molecular weight | 384.42 g/mol | Exact mass | ≥99% |
| PSA | 138.000 Ų | logp | 2.900 |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
